Mild cognitive impairment and preclinical Alzheimer's disease

Geriatrics. 2005 Jun;Suppl:9-14.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by a gradual decline of numerous cognitive processes, culminating in dementia. Mild cognitive impairment (MCI) is a relatively broad clinical condition involving a slight memory deficit, which in many cases represents a transitional state between normal cognition and AD. Much research is currently being conducted on MCI, since any therapy that is effective at treating this early manifestation of dementia may provide an opportunity for managing the disease while patient function is relatively preserved. Current research seeks to develop disease-modifying treatments that intervene in the pathobiologic processes involved in MCI and AD. Another goal of current research is to develop antecedent biomarkers that can be used to detect AD prior to the appearance of symptoms and before substantial and irreversible brain damage occurs.

Publication types

  • Review

MeSH terms

  • Activities of Daily Living
  • Aged
  • Aged, 80 and over
  • Aging / pathology
  • Alzheimer Disease* / classification
  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / physiopathology
  • Antiparkinson Agents / therapeutic use*
  • Cholinesterase Inhibitors / therapeutic use*
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy
  • Cognition Disorders / physiopathology*
  • Humans
  • Memantine / therapeutic use*
  • Middle Aged
  • Severity of Illness Index

Substances

  • Antiparkinson Agents
  • Cholinesterase Inhibitors
  • Memantine